Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) shares traded down 3.2% during trading on Friday . The stock traded as low as $15.93 and last traded at $15.98. 125,998 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 563,938 shares. The stock had previously closed at $16.50. […]
Prime Medicine (NYSE:PRME – Get Free Report) and Replimune Group (NASDAQ:REPL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares Prime […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) was down 4.2% during trading on Wednesday . The company traded as low as $17.01 and last traded at $17.08. Approximately 315,762 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 563,851 shares. The stock had previously closed at $17.83. […]
Panagora Asset Management Inc. raised its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 0.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 67,890 shares of the company’s stock after purchasing an additional 568 shares during the period. Panagora Asset Management Inc. owned […]
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $180....